Interaction Checker
Potential Interaction
Elbasvir/Grazoprevir
Rivaroxaban
Summary:
Rivaroxaban is a substrate of CYP3A4, P-gp, and BCRP. Coadministration may increase rivaroxaban concentrations due to the additive effect of weak inhibition of CYP3A4 by grazoprevir, mild inhibition of P-gp by elbasvir, and inhibition of BCRP by elbasvir/grazoprevir. A large, retrospective, multi-centre cohort study of patients coadministered HCV DAAs and DOACs, including elbasvir/grazoprevir and rivaroxaban, reported a low incidence of bleeding which was similar to historic controls of patients with liver disease on DOACs alone, providing reassurance that any increase in rivaroxaban levels is unlikely to be clinically relevant in the majority of patients. However, caution may be required if coadministration occurs in patients with moderate to severe renal impairment. Patients should be reminded to promptly report any signs of bleeding or bruising as with anyone who is prescribed DOACs. [Note: product labels state that rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C.]
Description:
View all available interactions with Elbasvir/Grazoprevir by clicking here.
Copyright © 2025 The University of Liverpool. All rights reserved.